Analysis of BMD and Serum Calcium Level in Patients with or without Bony Metastatic Breast Cancer
Keywords:
Breast cancer, Bony metastasis , Bone scan, Bone mineral density, Osteoporosis, Osteopenia, Serum calciumAbstract
Objective: To analyze bone mineral density (BMD) and serum calcium in patients with and without bony metastatic breast
cancer.
Materials and Methods: This descriptive study was conducted in KIRAN Hospital Karachi and Department of Biochemistry,
BMSI-JPMC Karachi from March 2011 to March 2012 .After approval by BASR of Karachi University 200 diagnosed cases
of breast cancer, reproductive and postmenopausal age group females, passing through any stage of cancer, married or unmarried,
lactating or non-lactating, having different body mass index, passing through any cycle of chemotherapy and radiotherapy were
selected. Consent of patients was taken on a form. Bone scan was done on Siemen E Cam scanner. Intravenous dye 20/mci
technetium 99 MDP has been used, to check the bone metastasis in breast cancer patients. Test for Bone Mineral Density was
done on Hologic software version 12. Serum calcium levels were checked on Selectra-E- semi auto biochemical analyzer.
Results: 40-49 years group showed highest number of cases of osteoporosis (24%). Bone scan positive patients showed
osteopenia (11%) in 40-49 years group. Distribution of subjects with osteopenia (15%) was more common in bone scan negative
patients especially in age group of 40-49 years. Serum calcium level was found to be comparatively increased in bone scan
positive patients than in bone scan negative patients again in age group 40-49.
Conclusion: In bone scan positive patients osteoporosis and serum calcium were high in comparison to bone scan negative
patients with most vulnerable age group being 40-49 years, in diagnosed cases of breast cancer
References
Howlader N, Noone AM, Krapcho M, Garshell J, Neym-an N. SEER cancer statistics Review, 1975-2010, Beth-esda da, MD: National cancer Institute; on November 2012 SEER
Yardley DA. Visceral disease in patients with metastatic breast cancer; efficacy and safety treatment with lxabe-pilone and other chemotherapeutic agents. Clin Breast Cancer 2010;10:64-73
Giuliamo M, Gioodano A, Jackson S, DeGiogi U, Mego M, Cohen EN Gao H et al. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Research 2014; 16:440.doi;10.1186/s13058-014-0440-8
Erdi YE, Humm JL, Imbeiaco M, Yeung H, Lason SM. Quantitative bone metastasis analysis based on image segmentation. J Nucl Med 1997; 38:1401-6
Soloway MS, Hardeman SW, Raymond J, Todd B, Sol-oway S. Stratification of patients with metastatic prostatic cancer based on initial bone scan. Cancer 1988; 61:195-202
Noguchi M, Kihuchi HI, Shilbashi M, Noda S. Percentage of positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer 2003; 88:195-201
Ulmeet D, Kobeteeh R, Fox JJ, Savage C, Evans MU, Lilja H et al. A novel automated platform for quantifying the extent of skeletal tumor involvement in prostate ca-ncer patients using the bone scan index. Eur Urol 2012; 62(1):78-84 doi10.1016/;eurero2012 01.037
Mitsui Y, Shilna H, Yamamoto Y, Haramoto M, Arichi N, Yasumoto H et al. Prediction of survival benefit using an automated bone scan index in patients with castration resistant prostate cancer. B I U Int 2012; 110:628-34 d-oi:10.1111/j.1464-410X 2012.11355
Kobetech R, Gjestsson P, Leek HK, Lomsly M, Ohlsson M, Sjosteand K et al. Progression of bone metastasis in patients with prostatic cancer – automated detection of new lesions and calculation of bone scan index. EJN-MMI Res 2013; 3(1):64.doi10.1186/2191-219X-3-64
Kaldelstam J, Sadik M, Edenbeandt L, Oblsson M. An-alysis of regional bone scan index measurements for the survival of patients with prostate cancer. Br Med Imaging 2014; 14:24. 147-2342/14 24
George SM, McTiernan A, Villasenor A, Atlano CM, Iruin ML. Disentengling the body weight bone mineral density association among breast cancer. Survivors an examination of the independent roles of lean mass and fat mass. BMC Cancer 2013; 13:497.doi:10.1186/1471-2407-13-497
Chen Z, Maricic M, Alagaki A, Moutou C, Arendell L, Lopez A et al. Feature risk increase after diagnosis of breast cancer or other cancers in postmenopausal women: results from the women’s health initiative. Osteoporosis 2009; 20(4):527-36
Edwards BJ, Raish DW, Shankalam V, McKoy JM, Gr-adishal W, Bunta AD et al. Cancer therapy associated bone loss: implications for hip fractures in mid life wom-en with breast cancer. Clin Cancer Res 2011; 17(3):560-8
Wintels-Stone KM, Schawetz AL, Hayiss C, Fabian CL, Campbell KL. A prospective model of care for breast cancer rehabilitation: bone health and arthalgias. Cancer 2012; 118(8 Suppl):2288-99
Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22: 2942–53
Whitlock JP, Evans AJ, Jackson L, Chan SY, Robertson JF. Imaging of metastatic breast cancer: distribution and radiological assessment at presentation. Clin Oncol 2001; 13:181–6
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical cancer research; Wetson Park Hospital Sheffield. United Kingdom 2006; 12(20 Suppl) doi:10.1158/1078-0432 CCR-06-093
Baker PJ, Holloway DL, Rasmussen AS, Muefely R. A single dose placebo controlled study of AMG 162, a full Human monoclonal antibody to RANK L, in postpausal women. J Bone Min Res 2004; 19 doi: 10, 1359/JB MR.040305
Farell E.C., Kaplan A. Clinical chemistry the C.V Mosby Co St Louis Toronto. Princeton 1984; 1051-1255 and 418
Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J. 2006; 12:S 70-80
Sandhu DS, Sandhu S, Karwasra RK, Marwah S. Profile of breast cancer patients at a tertiary care hospital in north India. Indian J Cancer. 2010; 47:16-22
Ali AA, Butt HA, Hassan J, Malik A, Qadir A, Ashraf A et al. Carcinoma Breast: a dilemma for our society. Ann King Edward Med Coll. 2003; 9:87-9
Boink AB, Buckley BM, Christiansen TF, Covington AK, Maas AH, Müller-Plathe O et al. Recommendation on sampling, transport, and storage for the determination of the concentration of ionized calcium in whole blood, plasma, and serum. IFC Scientific Division, Working Group on Ion-Selective Electrodes (WGSE). 1992; 4(4): 147-52
Hauschka PV, Mavarakos AE, Iafrati MD, Doleman SE, Klags-brun M. Growth factors in bone matrix. J Biol Chem 1986; 261:12665-74
Coleman RE, Rubens RD. The clinical course of bone metastasis from breast cancer. Br J Cancer 1987; 55:61-6.
Houssani N, Cortelloe CM. Imaging bone metastasis in breast cancer: evidence on comparative test accuracy. Ann Oncol Advan Access 2011; doi 10.1093/annonc /md.397
Fraenkel M, Novack V, Liel Y, Koretz M. Association between BMD and incidence of breast cancer. PLoS ONE 2013; 8(8):e70980
Rowan T, Clebow S, Johnson KC, Kooperberg C. Calci-um plus vitamin D3 supplementation and the risk of br-east cancer. J Natle Cancer Inst 2007; 100:1581-91
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2015 Hoor Fatima, Hafiz Rafiq Tagar, Afshan Chodhry, Shafqat Qamar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
